Last reviewed · How we verify
NCT07512830: HYPNOECHO
Evaluation of the Benefits of Hypnosis During Transoesophageal Echocardiography
NA trial testing conversational hypnosis in Cardio Vascular Disease in 150 participants. Currently enrolling.
15 October 2028
Quick facts
| Lead sponsor | Fondation Hôpital Saint-Joseph |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 150 |
| Start date | 18 February 2026 |
| Primary completion | 15 October 2028 |
| Estimated completion | 15 December 2028 |
| Sites | 1 location across France |
Drugs / interventions tested
- conversational hypnosis
Conditions studied
- Cardio Vascular Disease — all drugs for Cardio Vascular Disease →
Sponsor
Fondation Hôpital Saint-Joseph — full company profile →
Who can join
18 and older, any sex, with Cardio Vascular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Transoesophageal echocardiography (TOE) is a routine cardiology examination that is performed in most cases under local anaesthesia and is recommended for many indications.The objective of our study will be to evaluate the expected beneficial effect of using conversational hypnosis and hypnosis during a transoesophageal ultrasound examination performed directly in the examination room by the cardiologist conducting the examination.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07512830
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardio Vascular Disease
Currently open trials in the same condition.
- NCT07311512 — PMPR and Chlorhexidine on Periodontal Disease and Vascular Function · NA · recruiting
- NCT07237971 — Cocreating Action to Improve Rationality in the Health System · NA · recruiting
- NCT07205978 — Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis · active not recruiting
- NCT07085923 — Norwegian Mental Illness Heart Health Study · NA · recruiting
- NCT07062744 — The Role of Swan-Ganz Catheter in Hemodynamic Resuscitation for Patients With Cardiogenic Shock · NA · recruiting
Other Fondation Hôpital Saint-Joseph trials
Trials by the same sponsor.
- NCT07512908 — Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Di · NA · not yet recruiting
- NCT07512960 — Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization · Phase 3 · not yet recruiting
- NCT07348081 — Real World Evidence to Assess the Value of a Digital Care Coordination and Monitoring Program for Supporting Caregivers · NA · recruiting
- NCT07086612 — Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and Transverse Orthodontic Deficiency in Children · NA · recruiting
- NCT07081880 — Study of the Pathophysiological Mechanisms Involved in the SAPHO Syndrome: Genetic Component and Immune Response · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07512830 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondation Hôpital Saint-Joseph
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07512830.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing